IIL opens human vaccines plant at HyderabadIllustrative image – not actual.

Indian Immunologicals, a wholly owned subsidiary of National Dairy Development Board commenced operations at its new human vaccines plant and research and development (R&D) centre at Hyderabad, on 3 October 2003. The complex entailed an investment of Rs.58 crore.

 

The state-of-the-art plant will produce human vaccines such as recombitant hepatitis-B, measles, diphtheria, pertussis and tetanus besides new combination vaccines. The plant has the capacity to simultaneously manufacture 200 million doses of each vaccine per annum.

 

The vaccines will be exported under UNICEF’s vaccine procurement programme.

 

The R&D centre, set up at a cost of Rs.8 crore, will develop various animal and human vaccines and biologicals.  It may be noted that IIL is currently developing a DNA rabies vaccine in collaboration with Indian Institute of Science (IIS).

 

Related News

 

NDDB setting up human vaccines plant

← All latest storiesBack to top →